Immunohistochemistry for p16, but not Rb or p21, is an independent predictor of prognosis in conservatively treated, clinically localised prostate cancer

References

• Bott SR, Birtle AJ, Taylor CJ, Kirby RS. Prostate cancer management: (1) an update on localised disease. Postgrad Med J 2003; 79: 575–580.
   PubMedGoogle Scholar
• Albertsen PC. Is screening for prostate cancer with prostate specific antigen an appropriate public health measure? Acta Oncol 2005; 44: 255–264.
   PubMed Web of Science ®Google Scholar
• Cuzick J, Fisher G, Kattan MW, et al Long-term outcome among men with conservatively treated localised prostate cancer. Br J Cancer 2006; 95: 1186–1194.
   PubMed Web of Science ®Google Scholar
• Phillips SM, Morton DG, Lee SJ, Wallace DM, Neoptolemos JP. Loss of heterozygosity of the retinoblastoma and adenomatous polyposis susceptibility gene loci and in chromosomes 10p, 10q and 16q in human prostate cancer. Br J Urol 1994; 73: 390–395.
   PubMedGoogle Scholar
• Ittmann MM. Loss of heterozygosity on chromosomes 10 and 17 in clinically localized prostate carcinoma. Prostate 1996; 28: 275–281.
   PubMed Web of Science ®Google Scholar
• Brooks JD, Bova GS, Isaacs WB. Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinomas. Prostate 1995; 26: 35–39.
   Google Scholar
• Gao X, Chen YQ, Wu N, et al Somatic mutations of the WAF1/CIP1 gene in primary prostate cancer. Oncogene 1995; 11: 1395–1398.
   PubMedGoogle Scholar
• Lee CT, Capodieci P, Osman I, et al Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer. Clin Cancer Res 1999; 5: 977–983.
   PubMed Web of Science ®Google Scholar
• Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005; 293: 2095–2101.
   PubMed Web of Science ®Google Scholar
• Mucci LA, Pawitan Y, Demichelis F, et al Nine-gene molecular signature is not associated with prostate cancer death in a watchful waiting cohort. Cancer Epidemiol Biomarkers Prev 2008; 17: 249–251.
   Google Scholar
• Johansson JE, Andren O, Andersson SO, et al Natural history of early, localized prostate cancer. JAMA 2004; 291: 2713–2719.
   PubMed Web of Science ®Google Scholar
• Bookstein R, Rio P, Madreperla SA, et al Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. Proc Natl Acad Sci USA 1990; 87: 7762–7766.
   PubMed Web of Science ®Google Scholar
• Horowitz JM, Park SH, Bogenmann E, et al Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. Proc Natl Acad Sci USA 1990; 87: 2775–2779.
   PubMed Web of Science ®Google Scholar
• Theodorescu D, Broder SR, Boyd JC, Mills SE, Frierson HF Jr. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. J Urol 1997; 158: 131–137.
   PubMedGoogle Scholar
• Phillips SM, Barton CM, Lee SJ, et al Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostatic tumorigenesis. Br J Cancer 1994; 70: 1252–1257.
   Google Scholar
• Ittmann MM, Wieczorek R. Alterations of the retinoblastoma gene in clinically localized, stage B prostate adenocarcinomas. Hum Pathol 1996; 27: 28–34.
   PubMed Web of Science ®Google Scholar
• Maddison LA, Sutherland BW, Barrios RJ, Greenberg NM. Conditional deletion of Rb causes early stage prostate cancer. Cancer Res 2004; 64: 6018–6025.
   PubMed Web of Science ®Google Scholar
• Valassiadou KE, Stefanaki K, Tzardi M, et al Immunohistochemical expression of p53, bcl-2, mdm2 and waf1/p21 proteins in colorectal adenocarcinomas. Anticancer Res 1997; 17: 2571–2576.
   PubMed Web of Science ®Google Scholar
• Stein JP, Ginsberg DA, Grossfeld GD, et al Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst 1998; 90: 1072–1079.
   PubMed Web of Science ®Google Scholar
• Qin LF, Ng IO, Fan ST, Ng M. p21/WAF1, p53 and PCNA expression and p53 mutation status in hepatocellular carcinoma. Int J Cancer 1998; 79: 424–428.
   Google Scholar
• Caffo O, Doglioni C, Veronese S, et al Prognostic value of p21(WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up. Clin Cancer Res 1996; 2: 1591–1599.
   PubMed Web of Science ®Google Scholar
• Erber R, Klein W, Andl T, et al Aberrant p21(CIP1/WAF1) protein accumulation in head-and-neck cancer. Int J Cancer 1997; 74: 383–389.
   PubMedGoogle Scholar
• Sarbia M, Stahl M, zur Hausen A, et al Expression of p21WAF1 predicts outcome of esophageal cancer patients treated by surgery alone or by combined therapy modalities. Clin Cancer Res 1998; 4: 2615–2623.
   PubMedGoogle Scholar
• Aaltomaa S, Lipponen P, Eskelinen M, Ala-Opas M, Kosma VM. Prognostic value and expression of p21(waf1/cip1) protein in prostate cancer. Prostate 1999; 39: 8–15.
   PubMed Web of Science ®Google Scholar
• Rigaud J, Tiguert R, Decobert M, et al Expression of p21 cell cycle protein is an independent predictor of response to salvage radiotherapy after radical prostatectomy. Prostate 2004; 58: 269–276.
   Google Scholar
• Jarrard DF, Modder J, Fadden P, et al Alterations in the p16/pRb cell cycle checkpoint occur commonly in primary and metastatic human prostate cancer. Cancer Lett 2002; 185: 191–199.
   PubMed Web of Science ®Google Scholar
• Henshall SM, Quinn DI, Lee CS, et al Overexpression of the cell cycle inhibitor p16INK4A in high-grade prostatic intraepithelial neoplasia predicts early relapse in prostate cancer patients. Clin Cancer Res 2001; 7: 544–550.
   PubMedGoogle Scholar